Faculty, Staff and Student Publications
Language
English
Publication Date
1-8-2025
Journal
Communications Medicine
DOI
10.1038/s43856-024-00728-z
PMID
39779996
PMCID
PMC11711454
PubMedCentral® Posted Date
1-8-2025
PubMedCentral® Full Text Version
Post-print
Abstract
Background: Gene signatures derived from transcriptomic-causal networks offer potential for tailoring clinical care in cancer treatment by identifying predictive and prognostic biomarkers. This study aimed to uncover such signatures in metastatic colorectal cancer (CRC) patients to aid treatment decisions.
Methods: We constructed transcriptomic-causal networks and integrated gene interconnectivity into overall survival (OS) analysis to control for confounding genes. This integrative approach involved germline genotype and tumor RNA-seq data from 1165 metastatic CRC patients. The patients were enrolled in a randomized clinical trial receiving either cetuximab or bevacizumab in combination with chemotherapy. An external cohort of paired CRC normal and tumor samples, along with protein-protein interaction databases, was used for replication.
Results: We identify promising predictive and prognostic gene signatures from pre-treatment gene expression profiles. Our study discerns sets of genes, each forming a signature that collectively contribute to define patient subgroups with different prognosis and response to the therapies. Using an external cohort, we show that the genes influencing OS within the signatures, such as FANCI and PRC1, are upregulated in CRC tumor vs. normal tissue. These signatures are highly associated with immune features, including macrophages, cytotoxicity, and wound healing. Furthermore, the corresponding proteins encoded by the genes within the signatures interact with each other and are functionally related.
Conclusions: This study underscores the utility of gene signatures derived from transcriptomic-causal networks in patient stratification for effective therapies. The interpretability of the findings, supported by replication, highlights the potential of these signatures to identify patients likely to benefit from cetuximab or bevacizumab.
Keywords
Colorectal cancer, Computational biology and bioinformatics, Genetic interaction, Tumour biomarkers, Cancer genomics
Published Open-Access
yes
Recommended Citation
Yazdani, Akram; Lenz, Heinz-Josef; Pillonetto, Gianluigi; et al., "Gene Signatures Derived From Transcriptomic-Causal Networks Stratify Colorectal Cancer Patients for Effective Targeted Therapy" (2025). Faculty, Staff and Student Publications. 6011.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/6011
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons